Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.
Advertisement

Related Content

With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications
Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications

Topics

Advertisement
UsernamePublicRestriction

Register

PS066799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel